Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)

NCT07820566 | Recruiting

• 1 other identifier: 9310
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This is a study :

• Single-center
• Prospective
• Translational
• Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project. The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells. Translated with DeepL.com (free version)

Conditions

Kidney Cancers; Bladder Cancer; Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.

  For the establishment of the models, it is necessary to have: sufficient cell viability after enzymatic dissociation of the tissues and a correspondence of patient/model 3D therapeutic responses. The patients' blood will be collected to isolate immune cells using a Ficoll gradient, to integrate them into the forming 3D structures, taking into account the proportion present in the primary tumor tissues of each patient, for the 3D structures developed from their tumor.

  Day 1 after surgery

Interventions

Blood sample BIOLOGICAL

An additional 10 ml blood sample taken during a routine blood test

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* Male or female subject (≥18 years old); * Diagnosed with kidney cancer, prostate cancer, or bladder cancer; * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677)

You may qualify if:

• Criteria common to all patients:
• Male or female subject (≥18 years old);
• Diagnosed with kidney cancer, prostate cancer, or bladder cancer;
• whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677);
• affiliated with a social security health insurance scheme or beneficiary of such a scheme;
• agreeing to participate in the 3DBlood study.
• Specific criteria for patients with renal cell carcinoma (RCC):
• Extended nephrectomy (EN) (larger tumor, closer to the sinus; therefore at greater risk of metastasis): with a cavo, cavectomy (neoplastic thrombus in the vena cava), or renal vein bud, or lymph node dissection, or with adrenalectomy (often for tumors, therefore possible metastases).
• \- Partial nephrectomy (PN): with tumors at stage T2 or T3a)

You may not qualify if:

• Patient refusal to participate in the study;
• Inability to provide the subject with informed consent (subject in an emergency situation, difficulties in understanding the subject, etc.);
• Patient under legal protection, guardianship, or conservatorship;
• Patient currently participating in a therapeutic clinical trial (i.e., gene therapy or other).

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Chirurgie Urologique _ Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Kidney Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Urinary Bladder Diseases; Genital Neoplasms, Male; Genital Diseases, Male; Genital Diseases; Prostatic Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Hervé LANG, PUPH

CONTACT

33369550974; Herve.Lang@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2026
• First Posted: September 15, 2026
• Study Start: September 2, 2024
• Primary Completion (Estimated): September 1, 2029
• Study Completion (Estimated): September 1, 2029
• Last Updated: September 15, 2026

Record last verified: 2026-01

Locations

FR (1)